pharm-olanzapine olanzapine 7.5mg film-coated tablet blister pack
pharmacor pty ltd - olanzapine, quantity: 7.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; triacetin; isopropyl alcohol; pectin; titanium dioxide; magnesium stearate; hyprolose; mannitol; purified talc; purified water; propylene glycol; butan-1-ol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - olanzapine is indicated for the treatment of schizophrenia and related psychoses.,olanzapine alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.,olanzapine is indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.
pharm-olanzapine olanzapine 2.5mg film-coated tablet blister pack
pharmacor pty ltd - olanzapine, quantity: 2.5 mg - tablet, film coated - excipient ingredients: purified talc; hyprolose; magnesium stearate; lactose monohydrate; titanium dioxide; mannitol; isopropyl alcohol; pectin; purified water; triacetin; propylene glycol; butan-1-ol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - olanzapine is indicated for the treatment of schizophrenia and related psychoses.,olanzapine alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.,olanzapine is indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.
olanzapine-as olanzapine 2.5mg tablet blister pack
medis pharma pty ltd - olanzapine, quantity: 2.5 mg - tablet, film coated - excipient ingredients: crospovidone; magnesium stearate; purified talc; hyprolose; microcrystalline cellulose; lactose monohydrate; titanium dioxide; xanthan gum; polyvinyl alcohol; lecithin - for the treatment of schizophrenia and related psychoses. ,alone or in combination with lithium or valproate, it is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. ,for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.
olanzapine-as olanzapine 7.5mg tablet blister pack
medis pharma pty ltd - olanzapine, quantity: 7.5 mg - tablet, film coated - excipient ingredients: purified talc; crospovidone; magnesium stearate; lactose monohydrate; hyprolose; microcrystalline cellulose; titanium dioxide; xanthan gum; polyvinyl alcohol; lecithin - for the treatment of schizophrenia and related psychoses. ,alone or in combination with lithium or valproate, it is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. ,for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.
olanzapine tablet
tya pharmaceuticals - olanzapine (unii: n7u69t4szr) (olanzapine - unii:n7u69t4szr) - olanzapine 15 mg - olanzapine is indicated for the treatment of schizophrenia. efficacy was established in three clinical trials in adult patients with schizophrenia: two 6-week trials and one maintenance trial deciding among the alternative treatments available for adolescents, clinicians should consider the increased potential (in adolescents as compared with adults) for weight gain and hyperlipidemia. clinicians should consider the potential long-term risks when prescribing to adolescents, and in many cases this may lead them to consider prescribing other drugs first in adolescents . — oral olanzapine is indicated for the acute treatment of manic or mixed episodes associated with bipolar i disorder and maintenance treatment of bipolar i disorder. efficacy was established in three clinical trials in adult patients with manic or mixed episodes of bipolar i disorder: two 3- to 4-week trials and one monotherapy maintenance trial deciding among the alternative treatments available for adolescents, clinicians should consider
olanzapine tablet, film coated
ncs healthcare of ky, inc dba vangard labs - olanzapine (unii: n7u69t4szr) (olanzapine - unii:n7u69t4szr) - olanzapine 20 mg - oral olanzapine is indicated for the treatment of schizophrenia. efficacy was established in three clinical trials in adult patients with schizophrenia: two 6-week trials and one maintenance trial. in adolescent patients with schizophrenia (ages 13 to 17), efficacy was established in one 6-week trial [ see clinical studies (14.1)]. when deciding among the alternative treatments available for adolescents, clinicians should consider the increased potential (in adolescents as compared with adults) for weight gain and hyperlipidemia. clinicians should consider the potential long-term risks when prescribing to adolescents, and in many cases this may lead them to consider prescribing other drugs first in adolescents [see warnings and precautions (5.5, 5.6 ) ]. monotherapy - oral olanzapine is indicated for acute treatment of manic or mixed episodes associated with bipolar i disorder and maintenance treatment of bipolar i disorder. efficacy was established in three clinical trials in adult patients with manic
olanzapine- olanzapine tablet, film coated
teva pharmaceuticals usa inc - olanzapine (unii: n7u69t4szr) (olanzapine - unii:n7u69t4szr) - olanzapine 20 mg - oral olanzapine is indicated for the treatment of schizophrenia. efficacy was established in three clinical trials in adult patients with schizophrenia: two 6-week trials and one maintenance trial. in adolescent patients with schizophrenia (ages 13 to 17), efficacy was established in one 6-week trial [ see clinical studies (14.1)]. when deciding among the alternative treatments available for adolescents, clinicians should consider the increased potential (in adolescents as compared with adults) for weight gain and dyslipidemia. clinicians should consider the potential long-term risks when prescribing to adolescents, and in many cases this may lead them to consider prescribing other drugs first in adolescents [see warnings and precautions ( 5.5) ]. oral olanzapine is indicated for the acute treatment of manic or mixed episodes associated with bipolar i disorder and maintenance treatment of bipolar i disorder. efficacy was established in three clinical trials in adult patients with manic or mixed episode
olanzapine - olanzapine tablet, orally disintegrating
prasco laboratories - olanzapine (unii: n7u69t4szr) (olanzapine - unii:n7u69t4szr) - olanzapine 5 mg - olanzapine orally disintegrating tablets are indicated for the treatment of schizophrenia. efficacy was established in three clinical trials in adult patients with schizophrenia: two 6-week trials and one maintenance trial. in adolescent patients with schizophrenia (ages 13 to 17), efficacy was established in one 6-week trial [see clinical studies (14.1)] . when deciding among the alternative treatments available for adolescents, clinicians should consider the increased potential (in adolescents as compared with adults) for weight gain and dyslipidemia. clinicians should consider the potential long-term risks when prescribing to adolescents, and in many cases this may lead them to consider prescribing other drugs first in adolescents [see warnings and precautions (5.5)] . monotherapy — olanzapine orally disintegrating tablets are indicated for the acute treatment of manic or mixed episodes associated with bipolar i disorder and maintenance treatment of bipolar i disorder. efficacy was established in thr
olanzapine - olanzapine tablet, orally disintegrating
ajanta pharma limited - olanzapine (unii: n7u69t4szr) (olanzapine - unii:n7u69t4szr) - olanzapine 5 mg - oral olanzapine is indicated for the treatment of schizophrenia. efficacy was established in three clinical trials in adult patients with schizophrenia: two 6-week trials and one maintenance trial. in adolescent patients with schizophrenia (ages 13-17), efficacy was established in one 6-week trial [see clinical studies (14.1)] . when deciding among the alternative treatments available for adolescents, clinicians should consider the increased potential (in adolescents as compared with adults) for weight gain and dyslipidemia . clinicians should consider the potential long-term risks when prescribing to adolescents, and in many cases this may lead them to consider prescribing other drugs first in adolescents [see warnings and precautions (5.5)] . monotherapy — oral olanzapine is indicated for the acute treatment of manic or mixed episodes associated with bipolar i disorder and maintenance treatment of bipolar i disorder. efficacy was established in three clinical trials in adult patients with man
olanzapine tablet, orally disintegrating
tya pharmaceuticals - olanzapine (unii: n7u69t4szr) (olanzapine - unii:n7u69t4szr) - olanzapine 20 mg - olanzapine is indicated for the treatment of schizophrenia. efficacy was established in three clinical trials in adult patients with schizophrenia: two 6-week trials and one maintenance trial deciding among the alternative treatments available for adolescents, clinicians should consider the increased potential (in adolescents as compared with adults) for weight gain and hyperlipidemia. clinicians should consider the potential long-term risks when prescribing to adolescents, and in many cases this may lead them to consider prescribing other drugs first in adolescents . — oral olanzapine is indicated for the acute treatment of manic or mixed episodes associated with bipolar i disorder and maintenance treatment of bipolar i disorder. efficacy was established in three clinical trials in adult patients with manic or mixed episodes of bipolar i disorder: two 3- to 4-week trials and one monotherapy maintenance trial deciding among the alternative treatments available for adolescents, clinicians should consider